MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells

Mario Martínez Soldevilla; Helena Villanueva; Noelia Casares; Juan Jose Lasarte; Maurizio Bendandi; Susana Inoges; Ascensión López-Díaz de Cerio; Fernando Pastor

doi:10.18632/oncotarget.8095

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells

Mario Martínez Soldevilla, Helena Villanueva, Noelia Casares, Juan Jose Lasarte, Maurizio Bendandi, Susana Inoges, Ascensión López-Díaz de Cerio and Fernando Pastor _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:23182-23196. https://doi.org/10.18632/oncotarget.8095

Metrics: PDF 2400 views | HTML 3330 views | ?

Abstract

Mario Martínez Soldevilla1,2, Helena Villanueva1,2, Noelia Casares2,3, Juan Jose Lasarte2,3, Maurizio Bendandi4, Susana Inoges2,5, Ascensión López-Díaz de Cerio2,5 and Fernando Pastor1,2

1 Program of Molecular Therapies, Aptamer Unit, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain

2 Instituto de Investigación Sanitaria de Navarra (IDISNA), Recinto de Complejo Hospitalario de Navarra, Irunlarrea, Pamplona, Spain

3 Program Immunology and Immunotherapy, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain

4 Ross University School of Medicine, Roseau, Portsmouth, Commonwealth of Dominica

5 Clínica Universidad de Navarra, Pamplona, Spain

Correspondence to:

Fernando Pastor, email:

Keywords: aptamer, cancer immunotherapy, costimutaltion, targeting

Received: February 23, 2016 Accepted: February 28, 2016 Published: March 15, 2016

Abstract

In this work we show a clinically feasible strategy to convert in situ the own tumor into an endogenous vaccine by coating the melanoma cancerous cells with CD28 costimulatory ligands. This therapeutic approach is aimed at targeting T-cell costimulation to chemotherapy-resistant tumors which are refractory and been considered as untreatable cancers. These tumors are usually defined by an enrichment of cancer stem cells and characterized by the higher expression of chemotherapy-resistant proteins. In this work we develop the first aptamer that targets chemotherapy-resistant tumors expressing MRP1 through a novel combinatorial peptide-cell SELEX. With the use of the MRP1 aptamer we engineer a MRP1-CD28 bivalent aptamer that is able to bind MRP1-expressing tumors and deliver the CD28 costimulatory signal to tumor-infiltrating lymphocytes. The bi-specific aptamer is able to enhance costimulation in chemotherapy-resistant tumors. Melanoma-bearing mice systemically treated with MRP1-CD28 bivalent aptamer show reduced growth, thus proving an improved mice survival.

Besides, we have designed a technically feasible and translational whole-cell vaccine (Aptvax). Disaggregated cells from tumors can be directly decorated with costimulatory ligand aptamers to generate the vaccine Aptvax. CD28Aptvax made of irradiated tumor cells coated with the CD28-agonistic aptamer attached to MRP1 elicits a strong tumor- cell immune response against melanoma tumors reducing tumor growth.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8095

Publication Alerts

Research Papers:

MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells

Abstract